Although plasma NGAL has low indicating power for estimating the possibility of AKI progression or the optimal timing for RRT initiation [27], the fact that no biomarker is selected for screening or risk stratification purposes might be a potential shortcoming of this trial. This evidence concerns the gene LCN2 and acute kidney injury.